Type II Diabetes
In the U.S., type 2 diabetes currently affects 1 in 10 people and is expected to affect 1 in 3 people by 2050 1. Drug sales for type 2 diabetes were $23.4 billion in 2010, with an expected increase to $45 billion by 2020 2. Often, the absence of immediate noticeable treatment benefit leads to inadequate patient compliance. Unfortunately, severe manifestations of the disease, including blindness, kidney failure, neuropathy, and death, do not occur until years of improper treatment. Due to the staggering economic costs associated with diabetes ($245 billion in the U.S. alone 1). stakeholders are actively seeking treatments that improve compliance, and as a result, health outcomes.
GLP-1 receptor agonists are an increasingly utilized class of drugs for treating type 2 diabetes. There are currently 5 marketed drugs in this class, all of which require frequent injections, representing more than $2 billion in 2013 global sales. The market size for GLP-1 agonists is expected to reach nearly $8 billion by 2020 (17% CAGR 3).
Proven injectable type 2 diabetes treatment
High GLP-1 levels increases satiety through delayed gastric emptying.
Effective glycemic control
GLP-1 agonists enhance insulin sensitivity and insulin secretion.
Safe and effective treatment
Exenatide was first approved for treating type 2 diabetes in 2005.
Problems With Current Treatment
Too Many Needles
People don’t like injections
Injections can be painful and are generally avoided when possible.
Frequent administration is required
The short half-life of current GLP-1 agonists requires injections as often as twice-daily.
Poor patient compliance
Inadequate compliance leads to reduced patient outcomes.
How We Solve It
Only One Implant Is Necessary
Small device, simple insertion
NanoPortal implantation can be performed in a quick, outpatient procedure.
NanoPortal is being designed to last for durations of 3 months to 1 year.
Implantation ensures continuous dosing for the duration of the treatment.